ATE480244T1 - Neue, hyaluronsäure oder hyaluronsaure derivate und collagenase enthaltende pharmazeutische zusammensetzungen zur topischen behandlung von wunden, verbrennungen und geschwüren - Google Patents

Neue, hyaluronsäure oder hyaluronsaure derivate und collagenase enthaltende pharmazeutische zusammensetzungen zur topischen behandlung von wunden, verbrennungen und geschwüren

Info

Publication number
ATE480244T1
ATE480244T1 AT06754678T AT06754678T ATE480244T1 AT E480244 T1 ATE480244 T1 AT E480244T1 AT 06754678 T AT06754678 T AT 06754678T AT 06754678 T AT06754678 T AT 06754678T AT E480244 T1 ATE480244 T1 AT E480244T1
Authority
AT
Austria
Prior art keywords
hyaluronic acid
ulcers
wounds
burns
compositions containing
Prior art date
Application number
AT06754678T
Other languages
English (en)
Inventor
Susanna Vaccaro
Giovanni Gennari
Lanfranco Callegaro
Antonio Giannelli
Salvatore Caruso
Original Assignee
Fidia Farmaceutici
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici filed Critical Fidia Farmaceutici
Application granted granted Critical
Publication of ATE480244T1 publication Critical patent/ATE480244T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06754678T 2005-07-07 2006-07-05 Neue, hyaluronsäure oder hyaluronsaure derivate und collagenase enthaltende pharmazeutische zusammensetzungen zur topischen behandlung von wunden, verbrennungen und geschwüren ATE480244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000207A ITPD20050207A1 (it) 2005-07-07 2005-07-07 Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
PCT/EP2006/006616 WO2007006484A1 (en) 2005-07-07 2006-07-05 New pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers

Publications (1)

Publication Number Publication Date
ATE480244T1 true ATE480244T1 (de) 2010-09-15

Family

ID=37023161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06754678T ATE480244T1 (de) 2005-07-07 2006-07-05 Neue, hyaluronsäure oder hyaluronsaure derivate und collagenase enthaltende pharmazeutische zusammensetzungen zur topischen behandlung von wunden, verbrennungen und geschwüren

Country Status (15)

Country Link
US (3) US8900576B2 (de)
EP (1) EP1901755B1 (de)
JP (1) JP5322637B2 (de)
AT (1) ATE480244T1 (de)
AU (1) AU2006268950B2 (de)
BR (1) BRPI0612736A2 (de)
CA (1) CA2613976C (de)
DE (1) DE602006016799D1 (de)
DK (1) DK1901755T3 (de)
ES (1) ES2352350T3 (de)
IT (1) ITPD20050207A1 (de)
PL (1) PL1901755T3 (de)
PT (1) PT1901755E (de)
SI (1) SI1901755T1 (de)
WO (1) WO2007006484A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782622C (en) 2009-12-08 2018-05-22 Healthpoint, Ltd. Enzymatic wound debriding compositions with enhanced enzymatic activity
EP2570124B1 (de) * 2010-05-14 2016-11-02 Sanidad Y Residencias 21, S.A. Oleuropein zusammensetzungen zur behandlung von wunden und geschwüren bei älteren menschen und/oder diabetikern
KR101831918B1 (ko) 2010-06-11 2018-02-27 한국원자력의학원 히알루론산의 탈아세틸화 가수분해효소, 및 이에 의해 탈아세틸화된 히알루론산 및 이의 유도체
ES2385239B1 (es) * 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
JP6049714B2 (ja) 2011-07-20 2016-12-21 メディウンド リミテッド 結合組織疾患の治療のためのブロメライン由来タンパク質分解抽出物
EP4772625A2 (de) 2012-01-12 2026-07-08 Endo Biologics Limited Clostridium histolyticum enzym
CN102552479B (zh) * 2012-01-19 2013-12-04 孙万奎 一种用于治疗糖尿病足的中药组合物
ES2424294B1 (es) * 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
ITPD20120118A1 (it) 2012-04-18 2013-10-19 Fidia Farmaceutici "nuovo processo di produzione e purificazione dell'enzima collagenasi da vibrio alginolyticus"
ITPD20120173A1 (it) * 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
ITPD20120360A1 (it) * 2012-11-30 2014-05-31 Fidia Farmaceutici "nuovi geli viscoelastici in chirurgia oftalmica"
US20140328826A1 (en) * 2013-05-01 2014-11-06 COLE Research & Design, Inc. Product and method for treating keloid scars, hypertrophic scars and burn scars with contracture
US10117892B2 (en) * 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
EP3324925B1 (de) * 2015-07-23 2022-12-14 Mary Kay, Inc. Topische hautformulierungen
DK3589204T3 (da) 2017-03-01 2025-06-30 Endo Operations Ltd Apparat og fremgangsmåde til vurdering og behandling af cellulitis
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법
EP3675874B1 (de) * 2017-09-01 2023-11-29 Excel Med, LLC Pharmazeutische zusammensetzung zur behandlung von keloid und verwendungen davon
CN113759122A (zh) * 2020-06-05 2021-12-07 张曼 尿液蛋白质z及其多肽片段在烧伤中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4174389A (en) * 1977-05-13 1979-11-13 Cope Louise A Ophthalmic use of collagenase
IT1212892B (it) * 1983-10-11 1989-11-30 Della Valle Francesco Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
CA1227132A (fr) * 1983-01-05 1987-09-22 Robert J. Weill Preparation a activite collagenolytique ayant une activite elevee et compositions pharmaceutiques la contenant
DE3504905A1 (de) 1985-02-13 1986-08-14 J. Kühn GmbH & Co Präzisionswerkzeug KG, 4270 Dorsten Werkzeughalter o.dgl.
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
JP3449738B2 (ja) * 1991-07-10 2003-09-22 武田薬品工業株式会社 水溶性組成物
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
IL100112A (en) * 1991-11-21 1996-01-31 Yeda Res & Dev Microdelivery device for enhanced drug administration to the eye
DE4200080A1 (de) * 1992-01-03 1993-09-30 Reinmueller Johannes Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung
WO1994024273A1 (en) * 1993-04-16 1994-10-27 Baxter International Inc. Stable collagenase compositions and methods for their preparation
EP0637450A3 (de) 1993-08-04 1995-04-05 Collagen Corp Verfahren und Zusammensetzung zur Wiederbelebung von Nerbgewebe.
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US5718897A (en) 1995-06-07 1998-02-17 Trustees Of Tufts College Enhancing keratinocyte migration and proliferation
DE19641672A1 (de) * 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
IT1302534B1 (it) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
IT1306679B1 (it) 1999-06-29 2001-10-02 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico per la preparazione dicomposizoni farmaceutiche e biomateriali per la prevenzione della
JP2002020279A (ja) * 2000-06-30 2002-01-23 Taisho Pharmaceut Co Ltd 点眼液
DE10246340A1 (de) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung
EP1433845A1 (de) * 2002-12-23 2004-06-30 Georg-August-Universität Collagenase aus Clostridium tetani und ihre Verwendungen

Also Published As

Publication number Publication date
CA2613976A1 (en) 2007-01-18
AU2006268950A1 (en) 2007-01-18
DE602006016799D1 (de) 2010-10-21
EP1901755A1 (de) 2008-03-26
US9603910B2 (en) 2017-03-28
US20080206228A1 (en) 2008-08-28
US11040089B2 (en) 2021-06-22
SI1901755T1 (sl) 2011-01-31
HK1116683A1 (en) 2009-01-02
AU2006268950B2 (en) 2011-01-06
US20170209552A1 (en) 2017-07-27
WO2007006484A1 (en) 2007-01-18
BRPI0612736A2 (pt) 2012-10-02
PT1901755E (pt) 2010-12-16
PL1901755T3 (pl) 2011-03-31
JP2009500367A (ja) 2009-01-08
ES2352350T3 (es) 2011-02-17
EP1901755B1 (de) 2010-09-08
US20140377249A1 (en) 2014-12-25
DK1901755T3 (da) 2011-01-10
ITPD20050207A1 (it) 2007-01-08
US8900576B2 (en) 2014-12-02
CA2613976C (en) 2013-11-19
JP5322637B2 (ja) 2013-10-23

Similar Documents

Publication Publication Date Title
DE602006016799D1 (de) NEUE, HYALURONSÄURE ODER HYALURONSàURE DERIVATE UND COLLAGENASE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR TOPISCHEN BEHANDLUNG VON WUNDEN, VERBRENNUNGEN UND GESCHWÜREN
CA2931174C (en) No-emitting medical dressing comprising an no-generating module and a radiation-emitting module
Prasansuttiporn et al. Effect of reducing agents on bond strength to NaOCl-treated dentin
UY27486A1 (es) Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI0507198A (pt) derivados de bisariluréia
ATE232393T1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
CY1108992T1 (el) Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
ATE336255T1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
CY1109351T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν διαμινοοξειδαση
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
DE60135454D1 (de) Pharmazeutische gel-zusammensetzung
ATE486599T1 (de) Pharmazeutische zusammensetzung mit amlodipinbesilat und lisinoprildihydrat und herstellungsverfahren dafür
MD3076G2 (ro) Metodă de tratament al plăgilor necrotico-purulente la pacienţii cu picior diabetic
ATE454144T1 (de) Behandlung von malignen neoplasien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1901755

Country of ref document: EP